ALNY Alnylam Pharmaceuticals Inc.

104.54
-4.31  -4%
Previous Close 108.85
Open 105.14
Price To Book 8.22
Market Cap 11,820,586,710
Shares 113,072,381
Volume 742,676
Short Ratio
Av. Daily Volume 822,275
Stock charts supplied by TradingView

NewsSee all news

  1. Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2019 Financial Results

    SAN FRANCISCO, March 26, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ:VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today provided a corporate

  2. Vir Biotechnology Proceeding with Two Clinical Development Candidates for COVID-19

    - Multiple antibodies identified that neutralize SARS-CoV-2- Phase 1/2 clinical testing planned for this summer SAN FRANCISCO, March 25, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ:VIR) today

  3. Vir and Alnylam Expand Collaboration to Advance RNAi Therapeutics for the Treatment of Coronavirus Infection, Including COVID-19

     — Recent Alnylam advances in lung delivery technology suggest possible utility of siRNAs in targeting SARS-CoV-2 and other coronaviruses — Vir to lead development of potential coronavirus RNAi therapeutic candidates,

  4. Alnylam Announces Approval of GIVLAARI® (givosiran) in the European Union for the Treatment of Acute Hepatic Porphyria (AHP) in Adults and Adolescents

    − GIVLAARI is the First and Only Therapy Proven to Prevent AHP Attacks, Reduce Chronic Pain and Improve Quality of Life − − GIVLAARI Approved Based on ENVISION Phase 3 Study Results Showing a 74% Reduction in the Rate

  5. Alnylam Announces Changes to its Board of Directors

    − Appoints Dr. Olivier Brandicourt, Former CEO of Sanofi and Global Pharmaceutical Industry Leader − − Announces Retirement of Dr. Paul Schimmel, an Alnylam Co-founder, After Nearly Eighteen Years of Service

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

FDA approval announced November 20, 2019.
Givosiran
Acute hepatic porphyrias
Phase 3 data met all endpoints - September 25, 2019. Data November 18, 2019 noted LDL-C reductions of 50%.
Inclisiran - ORION-9
Hypercholesterolemia
Phase 1/2 additional details due 2Q 2020.
ALN-HBV02 (VIR-2218)
Chronic hepatitis B virus (HBV)
Rolling NDA filing has been initiated - January 10, 2020. To be completed early-2020. Full data from Phase 3 trial to be presented at the OxalEurope International Congress on March 31, 2020 in Amsterdam.
Lumasiran (ALN-GO1) ILLUMINATE-A
Primary Hyperoxaluria Type 1 (PH1)
FDA Approval announced August 10, 2018.
Patisiran
Familial Amyloidotic Polyneuropathy (FAP) in Patients with ATTR
Phase 2 trial ongoing.
ALN-CC5 (cemdisiran)
IgA nephropathy
Phase 3 enrolment ongoing - February 6, 2020.
Fitusiran (ATLAS)
Hemophilia
Phase 3 completion of enrolment announced February 18, 2020. Top-line data due early 2021.
ALN-TTRsc02 - HELIOS-A
ATTR amyloidosis
Phase 3 data met all endpoints - September 25, 2019. Detailed data due at AHA noted 58% LDL-C lowering.
Inclisiran - ORION-10
Cardiovascular disease (ASCVD)
Phase 3 trial met all primary and secondary efficacy endpoints. Noted September 2, 2019 a 54% LDL-C lowering after 11 months and 50% over 18 months.
Inclisiran - ORION 11
Cardiovascular disease (ASCVD)
Phase 1/2 initial data released.
ALN-AAT02
alpha-1 anti-trypsin deficiency-associated liver disease
Phase 3 top-line data due mid-2020.
Lumasiran (ALN-GO1) ILLUMINATE-B
Primary Hyperoxaluria Type 1
Phase 3 enrolment to be completed late-2020.
Patisiran APOLLO-B
Wild-type ATTR amyloidosis patients with cardiomyopathy
Phase 3 trial data due end of 2020.
Lumasiran (ALN-GO1) ILLUMINATE-C
Impaired renal function
Phase 1 trial ongoing.
ALN-AGT
Hypertension
Phase 3 trial has been initiated - noted November 22, 2019.
ALN-TTRsc02 (vutrisiran) - HELIOS-B
ATTR amyloidosis with cardiomyopathy

Latest News

  1. Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2019 Financial Results

    SAN FRANCISCO, March 26, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ:VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today provided a corporate

  2. Vir Biotechnology Proceeding with Two Clinical Development Candidates for COVID-19

    - Multiple antibodies identified that neutralize SARS-CoV-2- Phase 1/2 clinical testing planned for this summer SAN FRANCISCO, March 25, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ:VIR) today

  3. Vir and Alnylam Expand Collaboration to Advance RNAi Therapeutics for the Treatment of Coronavirus Infection, Including COVID-19

     — Recent Alnylam advances in lung delivery technology suggest possible utility of siRNAs in targeting SARS-CoV-2 and other coronaviruses — Vir to lead development of potential coronavirus RNAi therapeutic candidates,

  4. Alnylam Announces Approval of GIVLAARI® (givosiran) in the European Union for the Treatment of Acute Hepatic Porphyria (AHP) in Adults and Adolescents

    − GIVLAARI is the First and Only Therapy Proven to Prevent AHP Attacks, Reduce Chronic Pain and Improve Quality of Life − − GIVLAARI Approved Based on ENVISION Phase 3 Study Results Showing a 74% Reduction in the Rate

  5. Alnylam Announces Changes to its Board of Directors

    − Appoints Dr. Olivier Brandicourt, Former CEO of Sanofi and Global Pharmaceutical Industry Leader − − Announces Retirement of Dr. Paul Schimmel, an Alnylam Co-founder, After Nearly Eighteen Years of Service

  6. Alnylam Announces Approval in Brazil of ONPATTRO® for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy

    − ONPATTRO is the First-Ever RNAi Therapeutic Approved in Latin America – Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced that the Brazilian Health Regulatory Agency

  7. Alnylam to Webcast Presentations at Upcoming March Investor Conferences

    Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: Cowen & Company 40th Annual

  8. Alnylam to Webcast Presentation at 9th Annual SVB Leerink Global Healthcare Conference

    Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 9th Annual SVB Leerink Global Healthcare Conference on Thursday,

  9. Alnylam Completes Enrollment of HELIOS-A Phase 3 Study of Vutrisiran for the Treatment of hATTR Amyloidosis with Polyneuropathy

    – HELIOS-A Topline Results Expected in Early 2021 – Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced that it has achieved full enrollment in its HELIOS-A Phase 3 study

  10. Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Recent Period Activity

    − Achieved Fourth Quarter and Full Year 2019 ONPATTRO® (patisiran) Global Net Product Revenues of $55.8 Million and $166.4 Million, Respectively – − As of Year-End 2019, Over 750 Patients Worldwide Receiving

  11. Alnylam Receives Positive CHMP Opinion for GIVLAARI™ (givosiran) for the Treatment of Acute Hepatic Porphyria in Adults and Adolescents

    − European Commission Decision Expected in March − − Positive Opinion is Based on Data from the Pivotal ENVISION Phase 3 Study − Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company,

  12. Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2019 Financial Results

    Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2019 on Thursday, February 6,

  13. Alnylam Announces Preliminary* Fourth Quarter and Full Year 2019 Global Net Product Revenues and Provides Additional Commercial Updates

    − Achieved Fourth Quarter and Full Year 2019 ONPATTRO® (patisiran) Preliminary Global Net Product Revenues of Approximately $56 Million and $166 Million, Respectively – – As of Year-End 2019, Over 750 Patients

  14. Alnylam Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 (PH1)

    − Company Plans to Complete Submission in Early 2020 – – Lumasiran Granted Pediatric Rare Disease Designation by FDA for the Treatment of PH1 – Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi

  15. Alnylam to Webcast Presentation at 38th Annual J.P. Morgan Healthcare Conference

    Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 38th Annual J.P. Morgan Healthcare Conference on Monday, January

  16. Alnylam Reports Positive Topline Results from ILLUMINATE-A Phase 3 Study of Lumasiran for the Treatment of Primary Hyperoxaluria Type 1

    − Lumasiran Met Primary and All Tested Secondary Endpoints, with Significant Reduction in Urinary Oxalate Levels Relative to Placebo – − Alnylam Intends to File New Drug Application (NDA) and Marketing Authorisation

  17. Alnylam to Webcast Presentations at Upcoming December Investor Conferences

    Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: Evercore ISI 2nd Annual HealthCONx

  18. Alnylam Announces 2020 Product and Pipeline Goals and Provides Updates at R&D Day

    − Expects to Exceed Alnylam 2020 Goals with Four Marketed Products, 14 Organic Clinical Stage Programs, Including 6 in Late-Stage Development, Across 4 Strategic Therapeutic Areas (STArs), by End of 2020 – – Initiates

  19. Alnylam Announces New and Enhanced Framework for Value-Based Agreements to Accelerate Patient and Provider Access to GIVLAARI™ (givosiran)

    − Framework Ties Payment for GIVLAARI to its Delivery of Patient Outcomes in the Real-World Setting - − Includes New Approach Designed for Ultra-Rare Diseases that Gives Participating Payers Greater Financial

  20. Alnylam Announces Approval of GIVLAARI™ (givosiran) by the U.S. Food and Drug Administration (FDA)

    − GIVLAARI Approved for the Treatment of Adults with Acute Hepatic Porphyria (AHP) Based on ENVISION Phase 3 Study Results Showing Significant Reduction in the Rate of Porphyria Attacks in Patients with AHP – − FDA

  21. Alnylam Announces Second Annual Advocacy for Impact Grants Program

    − Program Aims to Inspire Creative Patient Advocacy Solutions to Unique Challenges in Rare Disease Communities − − Funding Will Support Unmet Needs in the ATTR Amyloidosis, Acute Hepatic Porphyria and Primary

  22. Alnylam to Webcast Presentation at Stifel 2019 Healthcare Conference

    Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Stifel 2019 Healthcare Conference on Tuesday, November 19, 2019

  23. Alnylam Initiates ILLUMINATE-C Phase 3 Study of Lumasiran for the Treatment of Advanced Primary Hyperoxaluria Type 1 and Presents New Positive Results from Phase 2 Open-Label Extension Study

    − Initial Results From ILLUMINATE-C Expected in Late 2020 – − In Phase 2 OLE, Lumasiran Treatment Resulted in 76 percent Mean Maximal Reduction in Urinary Oxalate Relative to Phase 1/2 Baseline – Alnylam

  24. Alnylam Pharmaceuticals Reports Third Quarter 2019 Financial Results and Highlights Recent Period Activity

    − Achieved Third Quarter 2019 ONPATTRO® Global Net Product Revenues of $46.1 Million, Including Initial Sales in Japan, with Over 600 Patients on Commercial Product Worldwide – − Initiated APOLLO-B Phase 3 Study of

  25. Alnylam Named #1 Biopharma Employer by Science Magazine

    Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced that Science magazine has named the company the world's number one employer in its annual survey of the biotech and

  26. Alnylam's Distinguished Chemist Mano Manoharan Receives Lifetime Achievement Award from the Oligonucleotide Therapeutics Society

    Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that Muthiah (Mano) Manoharan, Ph.D., Senior Vice President of Drug Innovation Chemistry at Alnylam, has been awarded

  27. Alnylam Announces Filing for Marketing Authorization of ONPATTRO® (patisiran) in Brazil for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy

    – Filing Marks the First RNAi Therapeutic to be Submitted for Potential Approval in Latin America – – Submission Made Under the Accelerated Regulatory Pathway for Rare Diseases – Alnylam Pharmaceuticals, Inc.

  28. Alnylam to Webcast Presentation at 2019 Cantor Global Healthcare Conference

    Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 2019 Cantor Global Healthcare Conference on Thursday, October 3,

  29. Alnylam Pharmaceuticals Announces Initiation of APOLLO-B Phase 3 Study of Patisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy

    – APOLLO-B Will Enroll Patients with Both Hereditary and Wild-Type Amyloidosis – Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced that the Company has initiated

  30. Alnylam Presents New Evidence Demonstrating Significant Association of V122I, a Highly Prevalent, Pathogenic Transthyretin (TTR) Mutation, with Clinical Diagnosis of Polyneuropathy

    Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today presented new results from an analysis of the UK Biobank – a prospective cohort study with genetic, physical, and health data on

  31. 1,000 Alnylam Employees Across the Globe Volunteer at 5th Annual Community Service Day

    − Alnylam Supports Nearly 40 Organizations in Greater Boston, Philadelphia, Europe and Brazil in "Helping Hands" Community Service Day – Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics

  32. Alnylam Presents New Clinical Results for Givosiran at the 2019 International Congress on Porphyrins and Porphyrias

    − Porphyria Attack Reductions Observed in ENVISION Phase 3 Study Maintained with Ongoing Givosiran Dosing in Open-Label Extension (OLE) Study – − In ENVISION Phase 3 Study, Patients Receiving Givosiran Reported

  33. Alnylam to Host Sixth Annual "RNAi Roundtable" Webcast Series

    Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that it plans to kick off its 6th annual series of "RNAi Roundtable" webcasts over the coming weeks. The series will

  34. Yumanity Therapeutics Appoints Patricia Allen to its Board of Directors

    Ms. Allen Brings Over 25 Years of Financial Leadership Experience to the Company Yumanity Therapeutics, a company focused on discovering and developing transformative therapies to treat neurodegenerative diseases,

  35. Alnylam Presents New Clinical Research Findings at the Second European Meeting of ATTR Amyloidosis for Doctors and Patients

    − Neurofilament Light Chain (NfL) Identified as a Potential Biomarker of Nerve Damage and Polyneuropathy due to hATTR Amyloidosis; ONPATTRO® (patisiran) Treatment Found to Reduce NfL Levels Relative to Placebo in APOLLO

  36. Alnylam Pharmaceuticals Provides Perspective on Positive Complete Results from ORION-11 Phase 3 Study of Inclisiran

    Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today provided perspective on the positive complete results from the ORION-11 Phase 3 study of inclisiran, an RNAi therapeutic in

  37. Alnylam to Webcast Presentation at 17th Annual Morgan Stanley Global Healthcare Conference

    Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 17th Annual Morgan Stanley Global Healthcare Conference on